Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Insulet Corporation - Common Stock (NQ: PODD )

260.70 +14.21 (+5.76%)
Streaming Delayed Price Updated: 12:20 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 191,553
Open 249.82
Bid (Size) 260.31 (2)
Ask (Size) 260.99 (2)
Prev. Close 246.49
Today's Range 249.81 - 261.00
52wk Range 160.19 - 289.46
Shares Outstanding 68,873,869
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Thursday's pre-market session: top gainers and losers in the S&P500 index
Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on S&P500 stock movements. 
Via Chartmill
$100 Invested In Insulet 15 Years Ago Would Be Worth This Much Today
Via Benzinga

Performance

YTD
+1.50%
+1.50%
1 Month
-4.87%
-4.87%
3 Month
-6.52%
-6.52%
6 Month
+11.01%
+11.01%
1 Year
+55.86%
+55.86%

More News

Read More
What's Driving the Market Sentiment Around Insulet?
Via Benzinga
BD, Teleflex, Insulet, UFP Technologies, and Haemonetics Shares Are Falling, What You Need To Know
Via StockStory
Topics Economy Government World Trade
Exposures Economy Political Tariff
What's Driving the Market Sentiment Around Insulet?
Via Benzinga
Q4 Patient Monitoring Earnings Review: First Prize Goes to Masimo (NASDAQ:MASI)
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
Is INSULET CORP (NASDAQ:PODD) on the Verge of a Major Breakout as a Strong Growth Stock?
Via Chartmill
Insulet to Announce First Quarter 2025 Financial Results on May 8, 2025
From Insulet Corporation
Via Business Wire
Q4 Earnings Highlights: iRhythm (NASDAQ:IRTC) Vs The Rest Of The Patient Monitoring Stocks
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Reasons Investors Love Insulet (PODD)
Via StockStory
Topics Stocks
Exposures US Equities
Here's How Much $1000 Invested In Insulet 15 Years Ago Would Be Worth Today
Via Benzinga
Patient Monitoring Stocks Q4 In Review: Insulet (NASDAQ:PODD) Vs Peers
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Insulet’s RADIANT Trial Demonstrates Meaningful Glycemic Improvements with the Omnipod® 5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections
From Insulet Corporation
Via Business Wire
Insulet Announces Pricing of Senior Notes Due 2033
From Insulet Corporation
Via Business Wire
Insulet Announces Proposed Financing Transactions
From Insulet Corporation
Via Business Wire
Insulet Expands Omnipod® 5 to Four More International Markets
From Insulet Corporation
Via Business Wire
From Injections to Innovation – Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod® 5 in Adults and Children with Type 1 Diabetes
From Insulet Corporation
Via Business Wire
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Insulet to Host Investor Day on June 5, 2025
From Insulet Corporation
Via Business Wire
Patient Monitoring Stocks Q4 Results: Benchmarking ResMed (NYSE:RMD)
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Exploring the Growth Potential of INSULET CORP (NASDAQ:PODD) as It Nears a Breakout.
Via Chartmill
1 Mid-Cap Stock on Our Watchlist and 2 to Ignore
Via StockStory
Reflecting On Patient Monitoring Stocks’ Q4 Earnings: DexCom (NASDAQ:DXCM)
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Which S&P500 stocks are moving on Tuesday?
Via Chartmill
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.